蒽基查尔酮：一种有前途的抗癌剂--结构和分子对接研究

IF 1.6 4区物理与天体物理 Q3 PHYSICS, CONDENSED MATTER

The European Physical Journal B Pub Date : 2024-11-26 DOI:10.1140/epjb/s10051-024-00822-0

Dian Alwani Zainuri, Nurfatin Najihah Nor Hashim, Nurul Syuhada Affandi, Nurfatiha Juliana Jamsari, Ibrahim Abdul Razak

{"title":"蒽基查尔酮：一种有前途的抗癌剂--结构和分子对接研究","authors":"Dian Alwani Zainuri, Nurfatin Najihah Nor Hashim, Nurul Syuhada Affandi, Nurfatiha Juliana Jamsari, Ibrahim Abdul Razak","doi":"10.1140/epjb/s10051-024-00822-0","DOIUrl":null,"url":null,"abstract":"<div><p>This study employed computational methods to investigate the potential anticancer activity of two anthracenyl chalcone derivatives: (<i>E</i>)-1-(anthracen-9-yl)-3-(4-dimethylamino)naphthalen-1-yl) prop-2-en-1-one (1) and (<i>E</i>)-1-(9-anthryl)-3-(2,6-dichlorophenyl)prop-2-en-1-one (2). Density Functional Theory (DFT) calculations with the B3LYP/6–311 + + G(d,p) basis set optimized the molecular structures. Hirshfeld surface analysis confirmed the presence of intermolecular interactions (C–H⋯O and C–H⋯π) within the crystal packing. Molecular docking simulations using Cavity-based Docking (CB-Dock) software revealed favorable binding within the active site of the target protein (PDB ID: 1M17). Compound 2 exhibited a slightly stronger binding affinity (− 10.1 kcal/mol) compared to compound 1 (− 9.2 kcal/mol), suggesting a tighter interaction. Both compounds interacted with crucial amino-acid residues (Leu 694, Phe 699, Val 702, Ala 719, Lys 721, Thr 766, Leu 768, Met 769, Pro 770, Gly 772, Cys 773, Arg 817, Asn 818, Leu 820, Thr 830, and Asp 831), including some previously identified as important for known anticancer agents targeting 1M17. These findings suggest the potential of these anthracenyl chalcone derivatives as novel anticancer agents.</p><h3>Graphical abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":787,"journal":{"name":"The European Physical Journal B","volume":"97 11","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1140/epjb/s10051-024-00822-0.pdf","citationCount":"0","resultStr":"{\"title\":\"Anthracenyl chalcone: a promising anticancer agent—structural and molecular docking studies\",\"authors\":\"Dian Alwani Zainuri, Nurfatin Najihah Nor Hashim, Nurul Syuhada Affandi, Nurfatiha Juliana Jamsari, Ibrahim Abdul Razak\",\"doi\":\"10.1140/epjb/s10051-024-00822-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This study employed computational methods to investigate the potential anticancer activity of two anthracenyl chalcone derivatives: (<i>E</i>)-1-(anthracen-9-yl)-3-(4-dimethylamino)naphthalen-1-yl) prop-2-en-1-one (1) and (<i>E</i>)-1-(9-anthryl)-3-(2,6-dichlorophenyl)prop-2-en-1-one (2). Density Functional Theory (DFT) calculations with the B3LYP/6–311 + + G(d,p) basis set optimized the molecular structures. Hirshfeld surface analysis confirmed the presence of intermolecular interactions (C–H⋯O and C–H⋯π) within the crystal packing. Molecular docking simulations using Cavity-based Docking (CB-Dock) software revealed favorable binding within the active site of the target protein (PDB ID: 1M17). Compound 2 exhibited a slightly stronger binding affinity (− 10.1 kcal/mol) compared to compound 1 (− 9.2 kcal/mol), suggesting a tighter interaction. Both compounds interacted with crucial amino-acid residues (Leu 694, Phe 699, Val 702, Ala 719, Lys 721, Thr 766, Leu 768, Met 769, Pro 770, Gly 772, Cys 773, Arg 817, Asn 818, Leu 820, Thr 830, and Asp 831), including some previously identified as important for known anticancer agents targeting 1M17. These findings suggest the potential of these anthracenyl chalcone derivatives as novel anticancer agents.</p><h3>Graphical abstract</h3>\\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>\",\"PeriodicalId\":787,\"journal\":{\"name\":\"The European Physical Journal B\",\"volume\":\"97 11\",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1140/epjb/s10051-024-00822-0.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The European Physical Journal B\",\"FirstCategoryId\":\"4\",\"ListUrlMain\":\"https://link.springer.com/article/10.1140/epjb/s10051-024-00822-0\",\"RegionNum\":4,\"RegionCategory\":\"物理与天体物理\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHYSICS, CONDENSED MATTER\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The European Physical Journal B","FirstCategoryId":"4","ListUrlMain":"https://link.springer.com/article/10.1140/epjb/s10051-024-00822-0","RegionNum":4,"RegionCategory":"物理与天体物理","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHYSICS, CONDENSED MATTER","Score":null,"Total":0}

引用次数: 0

摘要

本研究采用计算方法研究了两种蒽基查尔酮衍生物的潜在抗癌活性：(E)-1-(蒽-9-基)-3-(4-二甲基氨基)萘-1-基)丙-2-烯-1-酮(1)和(E)-1-(9-蒽基)-3-(2,6-二氯苯基)丙-2-烯-1-酮(2)。利用 B3LYP/6-311 + + G(d,p) 基集进行的密度泛函理论（DFT）计算优化了分子结构。Hirshfeld 表面分析证实了晶体结构中存在分子间相互作用（C-H⋯O 和 C-H⋯π）。使用基于空穴的对接（CB-Dock）软件进行的分子对接模拟显示，化合物 2 与目标蛋白质（PDB ID：1M17）的活性位点结合良好。与化合物 1（- 9.2 kcal/mol）相比，化合物 2 的结合亲和力稍强（- 10.1 kcal/mol），表明其相互作用更紧密。这两种化合物都与关键的氨基酸残基（Leu 694、Phe 699、Val 702、Ala 719、Lys 721、Thr 766、Leu 768、Met 769、Pro 770、Gly 772、Cys 773、Arg 817、Asn 818、Leu 820、Thr 830 和 Asp 831）发生了相互作用，其中包括一些先前被确定为对靶向 1M17 的已知抗癌剂很重要的氨基酸残基。这些发现表明这些蒽基查尔酮衍生物具有作为新型抗癌剂的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Anthracenyl chalcone: a promising anticancer agent—structural and molecular docking studies

This study employed computational methods to investigate the potential anticancer activity of two anthracenyl chalcone derivatives: (E)-1-(anthracen-9-yl)-3-(4-dimethylamino)naphthalen-1-yl) prop-2-en-1-one (1) and (E)-1-(9-anthryl)-3-(2,6-dichlorophenyl)prop-2-en-1-one (2). Density Functional Theory (DFT) calculations with the B3LYP/6–311 + + G(d,p) basis set optimized the molecular structures. Hirshfeld surface analysis confirmed the presence of intermolecular interactions (C–H⋯O and C–H⋯π) within the crystal packing. Molecular docking simulations using Cavity-based Docking (CB-Dock) software revealed favorable binding within the active site of the target protein (PDB ID: 1M17). Compound 2 exhibited a slightly stronger binding affinity (− 10.1 kcal/mol) compared to compound 1 (− 9.2 kcal/mol), suggesting a tighter interaction. Both compounds interacted with crucial amino-acid residues (Leu 694, Phe 699, Val 702, Ala 719, Lys 721, Thr 766, Leu 768, Met 769, Pro 770, Gly 772, Cys 773, Arg 817, Asn 818, Leu 820, Thr 830, and Asp 831), including some previously identified as important for known anticancer agents targeting 1M17. These findings suggest the potential of these anthracenyl chalcone derivatives as novel anticancer agents.